Scinai Immunotherapeutics logo

Scinai Immunotherapeutics(NASDAQ) SCNI

Market Cap$531.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-100%
5 Year-100%
1 Year-95%
1 Month-51%
$0.72
-4.13%
-0.03Today
Scinai Immunotherapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.752026-10-16
Scinai Immunotherapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-36.24%USD 1.182026-10-09
1 month-50.5%USD 1.522026-09-16
3 month-69.88%USD 2.502026-07-17
Year to date-89.43%USD 7.122025-12-31
1 year-94.85%USD 14.602025-10-16
3 year-99%USD 75.002023-10-17
5 year-99.97%USD 2,210.002021-10-15
Since inception-99.98%USD 3,990.002015-05-12

Scinai Immunotherapeutics Financials at a Glance

Market Cap

$531.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.49M

Net Income (TTM)

-$2.64M

EPS (TTM)

-$47.55

P/E Ratio

-0.02

Dividend

$0.00

Beta (Volatility)

1.02 (Average)

Price

$0.72

Volume

94,244.117

Open

$0.75

Previous Close

$0.75

Daily Range

$0.66 - $0.75

52-Week Range

$0.66 - $15.50

Estimated Earnings Date

Dec 2, 2026

SCNI News

GettyImages-459898185

Why BiondVax Pharmaceuticals Stock Imploded Today

Prosper Junior BakinyOct 23, 2020

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. is an emerging biopharmaceutical company focused on developing innovative medical solutions for infectious and autoimmune diseases. Based in Israel, the company aims to advance its proprietary nanosized antibody technology, particularly for COVID-19 and other health conditions.

Products and Services
  • Development of nanosized antibodies (NanoAbs) for various diseases
  • Collaboration with Max Planck Society and University Medical Center Göttingen
  • Research and production of immunotherapeutic solutions
Growth Outlook
  • Partnerships with leading research institutions enhance innovation potential
  • Focus on expanding applications of NanoAb technology across multiple diseases
  • Strategic positioning in the growing biopharmaceutical market
Financial Highlights
  • Recent quarterly revenue of $467,898, showing potential for growth
  • Trailing twelve months (TTM) revenue of $1,214,000, indicating market interest
  • Cash and cash equivalents of $2,852,979, providing operational stability
Scinai Immunotherapeutics Ltd. operates in a dynamic sector with significant growth potential. The company's focus on innovative therapeutic solutions, particularly through its NanoAb technology, positions it well within the biopharmaceutical landscape. Collaborations with prestigious institutions further enhance its research capabilities, potentially leading to breakthroughs in treatment options. Recent financial data reflects a growing interest in the company's offerings, with a solid cash position to support ongoing operations and development efforts. As the biopharmaceutical market continues to expand, Scinai Immunotherapeutics Ltd. stands out as a company to watch.
AI Generated • Sep 26, 2026

Industry

Biotechnology

Sector

Health Care

Employees

45

CEO

Amir Reichman, MBA

Website

www.scinai.com

Headquarters

Jerusalem, JM 9112001, IL

SCNI Financials

Key Financial Metrics (TTM)

Gross Margin

-252.45%

Operating Margin

-563.89%

Net Income Margin

-176.96%

Return on Equity

-26.63%

Return on Capital

-72.73%

Return on Assets

-15.39%

Earnings Yield

-50.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$531.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

706.60K

Volume

94.24K

Avg. Volume

2.11M

Financials (TTM)

Gross Profit

-$3.77M

Operating Income

-$8.42M

EBITDA

-$6.66M

Operating Cash Flow

-$7.40M

Capital Expenditure

-$127.81K

Free Cash Flow

-$7.53M

Cash & ST Invst.

$2.85M

Total Debt

$3.58M

Scinai Immunotherapeutics Performance Analysis

Scinai Immunotherapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 661,123N/A
20252025-12-31USD 1,321,40099.9%
Scinai Immunotherapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-30.4%
Q42025-12-31N/A
Q12026-03-3181.3%
Q22026-06-30-4.1%
Scinai Immunotherapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -306.40-65.1%
20232023-12-31USD -165.97-45.8%
20242024-12-31USD 59.88N/A
20252025-12-31USD -35.88N/A
Scinai Immunotherapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-815233.3%
Q42025-12-3197.2%
Q12026-03-311511.8%
Q22026-06-30-100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$467.90K

+21.1%

Gross Profit

-$1.27M

-100.6%

Gross Margin

-2.72%

N/A

Market Cap

$531.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$11.81K

N/A

Employees

45

N/A

Net Income

-$2.04M

+1.4%

EBITDA

-$1.59M

-3.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$2.85M

+188.5%

Total Debt

$3.58M

+52.0%

Accounts Receivable

$74.00K

-46.8%

Inventory

$0.00

N/A

Long Term Debt

$3.21M

+72.7%

Short Term Debt

$369.00K

-25.8%

Return on Assets

-15.39%

N/A

Return on Invested Capital

-56.36%

N/A

Free Cash Flow

-$2.61M

-69.7%

Operating Cash Flow

-$2.50M

-62.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SPRCSciSparc Ltd.
$1.42-16.46%
PBMPsyence Biomedical Ltd.
$4.12-2.37%
SLXNSilexion Therapeutics Ltd.
$0.16+1.83%
ONCOOnconetix, Inc.
$0.43-10.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$99.04+5.73%
INTCIntel
$92.49+2.94%
CRWVCoreWeave
$60.33-1.73%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$46.43-5.69%

Questions About SCNI

What is the current price of Scinai Immunotherapeutics?

Scinai Immunotherapeutics is trading at $0.72 per share.

What is the 52-week range for Scinai Immunotherapeutics?

Over the past 52 weeks, Scinai Immunotherapeutics has traded between $0.66 and $15.50.

How much debt does Scinai Immunotherapeutics have?

As of the most recent reporting period, Scinai Immunotherapeutics reported total debt of $3.58M.

How much cash does Scinai Immunotherapeutics have on hand?

Scinai Immunotherapeutics reported $2.85M in cash and cash equivalents in its most recent financial results.

What is Scinai Immunotherapeutics’s dividend yield?

Scinai Immunotherapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services